5-(2H-tetrazol-5-yl)pyridin-2-amine | 13566-35-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(2H-tetrazol-5-yl)pyridin-2-amine
• 英文别名: 5-(1H-tetrazol-5-yl)-pyridin-2-ylamine；5-(2H-tetrazol-5-yl)-pyridin-2-ylamine；5-(1H-tetrazol-5-yl)pyridin-2-amine
• CAS: 13566-35-3
• 化学式: C₆H₆N₆
• mdl: MFCD18258940
• 分子量: 162.154
• InChiKey: IAGOSDIWNXIKMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  93.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(2H-tetrazol-5-yl)pyridin-2-amine 在 sodium hydride 、 一水合肼 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.5h， 生成 N-(5-(2-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-yl)methyl)-2H-tetrazol-5-yl)pyridin-2-yl)-2,2-difluoroacetamide
  参考文献：
  名称：

  [EN] 2-(4-((5-(BENZO[B]THIOPHEN-3-YL)-1H-TETRAZOL-1-YL)METHYL)PHENYL)-5-(DIFLUOROMETHYL)-1,3,4-OXADIAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASE 6 (HDAC6) FOR USE IN TREATING E.G. PERIPHERAL NEUROPATHY
  [FR] DÉRIVÉS DE 2-(4-((5-(BENZO[B]THIOPHÉN-3-YL)-1H-TÉTRAZOL-1-YL)MÉTHYL)PHÉNYL)-5-(DIFLUOROMÉTHYL)-1,3,4-OXADIAZOLE ET COMPOSÉS SIMILAIRES EN TANT QU'INHIBITEURS SÉLECTIFS DE L'HISTONE DÉSACÉTYLASE 6 (HDAC6) POUR UNE UTILISATION DANS LE TRAITEMENT, PAR EXEMPLE, DE LA NEUROPATHIE PÉRIPHÉRIQUE

  摘要：

  公式为（I）的化合物是选择性组织脱乙酰化酶6（HDAC6）抑制剂，用于治疗外周神经病、移植排斥、GVHD、肌炎、与异常淋巴细胞功能相关的疾病、多发性骨髓瘤、非何杰金淋巴瘤、自身免疫性疾病、炎症性疾病、癌症和神经退行性病理学。首选化合物是例如2-（4-（（5-（苯并[b]噻吩-3-基）-1H-四唑-1-基）甲基）苯基）-5-（二氟甲基）-1,3,4-噁唑衍生物及相关化合物。

  公开号：

  WO2022029041A1
• 作为产物：
  描述：

  2-氨基-5-氰基吡啶 在 sodium azide 、 氯化铵 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 5-(2H-tetrazol-5-yl)pyridin-2-amine
  参考文献：
  名称：

  WO2006/92599

  摘要：

  公开号：

文献信息

• Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
  申请人：Eisai R&D Managment Co., Ltd.

  公开号：US08183264B2

  公开（公告）日：2012-05-22

  The present invention provides an antifungal agent that has excellent antifungal action, and is also excellent in terms of its properties, safety, and metabolic stability. The present invention discloses a compound represented by the following formula I or a salt thereof, and an antifungal agent comprising the compound or the salt: wherein R1 represents a hydrogen atom, a halogen atom, an amino group, a C1-6 alkyl group, a C1-6 alkoxy group, or a C1-6-alkoxy-C1-6-alkyl group; R2 represents a hydrogen atom or an amino group; X, Y, Z, and W independently represent a nitrogen atom, an oxygen atom, a sulfur atom, or —CH—, provided that at least two among X, Y, and W are nitrogen atoms; the ring A represents a 5- or 6-membered heteroaryl ring or a benzene ring; Q represents a methylene group, an oxygen atom, —CH2O—, —OCH2—, —NH—, —NHCH2—, or —CH2NH—; and R3 represents a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, or a 5- or 6-membered heteroaryl group, each of which may have one or two substituents.

  本发明提供了一种具有优异的抗真菌作用、性质、安全性和代谢稳定性的抗真菌剂。本发明披露了以下式I或其盐所代表的化合物，以及包含该化合物或其盐的抗真菌剂：其中R1表示氢原子、卤素原子、氨基、C1-6烷基、C1-6烷氧基或C1-6-烷氧基-C1-6-烷基；R2表示氢原子或氨基；X、Y、Z和W独立地表示氮原子、氧原子、硫原子或-CH-，其中至少有两个是氮原子；环A表示5-或6-成员杂环芳基环或苯环；Q表示亚甲基、氧原子、-CH2O-、-OCH2-、-NH-、-NHCH2-或-CH2NH-；R3表示C1-6烷基、C3-8环烷基、C6-10芳基或5-或6-成员杂环基，每个基团可以有一个或两个取代基。
• PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2065377B1

  公开（公告）日：2011-11-23
• Discovery of (<i>S</i>)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1<i>H</i>-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus
  作者：Jeffrey A. Pfefferkorn、Angel Guzman-Perez、John Litchfield、Robert Aiello、Judith L. Treadway、John Pettersen、Martha L. Minich、Kevin J. Filipski、Christopher S. Jones、Meihua Tu、Gary Aspnes、Hud Risley、Jianwei Bian、Benjamin D. Stevens、Patricia Bourassa、Theresa D’Aquila、Levenia Baker、Nicole Barucci、Alan S. Robertson、Francis Bourbonais、David R. Derksen、Margit MacDougall、Over Cabrera、Jing Chen、Amanda Lee Lapworth、James A. Landro、William J. Zavadoski、Karen Atkinson、Nahor Haddish-Berhane、Beijing Tan、Lili Yao、Rachel E. Kosa、Manthena V. Varma、Bo Feng、David B. Duignan、Ayman El-Kattan、Sharad Murdande、Shenping Liu、Mark Ammirati、John Knafels、Paul DaSilva-Jardine、Laurel Sweet、Spiros Liras、Timothy P. Rolph

  DOI：10.1021/jm2014887

  日期：2012.2.9

  Glucokinase is a key regulator of glucose homeostasis, and small molecule allosteric activators of this enzyme represent a promising opportunity for the treatment of type 2 diabetes. Systemically acting glucokinase activators (liver and pancreas) have been reported to be efficacious but in many cases present hypoglycaemia risk due to activation of the enzyme at low glucose levels in the pancreas, leading to inappropriately excessive insulin secretion. It was therefore postulated that a liver selective activator may offer effective glycemic control with reduced hypoglycemia risk. Herein, we report structure-activity studies on a carboxylic acid containing series of glucokinase activators with preferential activity in hepatocytes versus pancreatic beta-cells. These activators were designed to have low passive permeability thereby minimizing distribution into extrahepatic tissues; concurrently, they were also optimized as substrates for active liver uptake via members of the organic anion transporting polypeptide (OATP) family. These studies lead to the identification of 19 as a potent glucokinase activator with a greater than 50-fold liver-to-pancreas ratio of tissue distribution in rodent and non-rodent species. In preclinical diabetic animals, 19 was found to robustly lower fasting and postprandial glucose with no hypoglycemia, leading to its selection as a clinical development candidate for treating type 2 diabetes.
• US7696217B2
  申请人：——

  公开号：US7696217B2

  公开（公告）日：2010-04-13
• US8183264B2
  申请人：——

  公开号：US8183264B2

  公开（公告）日：2012-05-22